The combination of acimtamig and AlloNK® therapy demonstrates promising efficacy in R/R cHL

Dr Amitkumar Mehta speaks to ecancer about Acimtamig (AFM13) in combination with AlloNK® (AB-101) in patients with relapsed or refractory classical Hodgkin lymphoma: Results from the dose finding phase of the LUMINICE-203 phase 2 study.

This study on relapse refractory classical Hodgkin's lymphoma enrolls 24 patients to test a bispecific antibody and NK cells.

Most participants had limited options after previous treatments.

The study shows an 88% overall response rate and a 58% complete response rate.

New treatment combinations are proving effective, can be given outpatient, and have manageable toxicity, providing immediate access for patients.